BioCatalystWatch
RVMDWorkspace / RVMD / OverviewCompany library
Revolution Medicines, Inc. logo

Revolution Medicines, Inc.

Revolution Medicines, Inc. (RVMD)

Website

Price
Market cap
Next catalystExpected Q4 2026Zoldonrasib plus cetuximab and FOLFOX or FOLFIRI — RASonate 312 · Trial initiationCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

Daraxonrasib

Oncogenic RAS(ON)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Daraxonrasib

Oncogenic RAS(ON)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Daraxonrasib

Oncogenic RAS(ON)

Upcoming / outlook

Daraxonrasib

Oncogenic RAS(ON)

PreINDP1P2P3FilingApproved
Daraxonrasib

Oncogenic RAS(ON)

PreINDP1P2P3FilingApproved
Upcoming / outlook

RM-055

Mutant RAS(ON) × KRAS G12

Upcoming / outlook

Elironrasib (RMC-6291)

KRAS G12C(ON) × Cyclophilin A (CYPA)

PreINDP1P2P3FilingApproved
New class of RAS(ON) inhibitors

Mutant RAS(ON)

PreINDP2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Daraxonrasib

Oncogenic RAS(ON)

Upcoming / outlook

RM-055

Mutant RAS(ON) × KRAS G12

Upcoming / outlook

New class of RAS(ON) inhibitors

Mutant RAS(ON)

PreINDP2P3FilingApproved
Upcoming / outlook

Daraxonrasib

Oncogenic RAS(ON)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Daraxonrasib

Oncogenic RAS(ON)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

RMC-5552

mTORC1

PreINDP1P2P3FilingApproved
Daraxonrasib

Oncogenic RAS(ON)

PreINDP1P2P3FilingApproved
Daraxonrasib

Oncogenic RAS(ON)

PreINDP1P2P3FilingApproved
Daraxonrasib

Oncogenic RAS(ON) and RAS G12D(ON)

PreINDP1P2P3FilingApproved

Oncogenic RAS(ON) + KRAS G12D(ON)

PreINDP1P2P3FilingApproved
Elironrasib (RMC-6291)

KRAS G12C(ON) × Cyclophilin A (CYPA)

PreINDP1P2P3FilingApproved
Elironrasib (RMC-6291)

KRAS G12C(ON) × Cyclophilin A (CYPA)

PreINDP1P2P3FilingApproved

KRAS G12C(ON) × Cyclophilin A (CYPA)

PreINDP1P2P3FilingApproved

Partner / License out

Zoldonrasib plus cetuximab and FOLFOX or FOLFIRI — RASonate 312

KRAS G12D(ON)

PreINDP1P2FilingApproved
Upcoming / outlook

Approved / commercial

History / paused

Daraxonrasib

Oncogenic RAS(ON)

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

RVMD PR & News

PR & News

RVMD SEC archive